Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

H F Zhao

Showing results (71-80 of 82) with videos related to

Pageof 9
Sort By:
Zhonghua Xue Ye Xue Za Zhi = Zhonghua Xueyexue Zazhi|April 29, 2021
[Hereditary coagulation factor XIII deficiency: three cases report and literaure review]P P Xu, B J Ding, M J Li, et al.
Journal of Synchrotron Radiation|December 20, 2008
Correlation between local vibrations and metal mass in AlB2-type transition-metal diboridesW S Chu, S Zhang, M J Yu, et al.
Zhonghua Xue Ye Xue Za Zhi = Zhonghua Xueyexue Zazhi|January 28, 2023
[Observational study of chronic myeloid leukemia Chinese patients who discontinued tyrosine kinase inhibitors in the real-world]H F Zhao, Y F Yang, B C Liu, et al.
Zhonghua Yi Xue Za Zhi|June 12, 2022
[Analysis the influence factors of treatment free remission outcome with chronic myeloid leukemia patients who discontinued tyrosine kinase inhibitors]H F Zhao, Yanli Zhang, L X Dang, et al.
Zhonghua Xue Ye Xue Za Zhi = Zhonghua Xueyexue Zazhi|November 17, 2021
[CMV-CTL for treatment of refractory CMV infection in 17 patients following alternative donor hematopoietic stem cell transplantation]R R Gui, Z Li, Y L Zu, et al.
Zhonghua Yi Xue Za Zhi|November 5, 2024
[Analysis of treatment-free remission outcomes in patients with chronic myeloid leukemia who received sequential nilotinib therapy after achieving deep molecular response to imatinib]H F Zhao, H B Dang, L X Liang, et al.
Zhonghua Xue Ye Xue Za Zhi = Zhonghua Xueyexue Zazhi|May 21, 2019
[Successful treatment of Epstein-Barr virus associated central nervous system diseases after allogeneic hematopoietic stem cell transplantation with intrathecal donor lymphocytes infusion: three cases report and literatures review]R R Gui, Y L Zu, Yanli Zhang, et al.
Zhonghua Xue Ye Xue Za Zhi = Zhonghua Xueyexue Zazhi|October 30, 2018
[Clinical analysis of six cases with the <i>de novo</i> glomerulitis after allogeneic hematopoietic stem cell transplantation]J Zhou, Y L Zu, R R Gui, et al.
Zhonghua Nei Ke Za Zhi|January 5, 2021
[Risk factors of extramedullary relapse after allogeneic hematopoietic stem cell transplantation in patients with myeloid leukemia]Y L Zu, J Zhou, Yanli Zhang, et al.
Zhonghua Xue Ye Xue Za Zhi = Zhonghua Xueyexue Zazhi|October 27, 2025
[Identify the factors associated with treatment-free remission outcomes after imatinib discontinuation in children and adolescent patients with chronic myeloid leukemia]H F Zhao, Q Jiang, W M Li, et al.
Pageof 9

Showing results (71-80 of 82) with videos related to

Sort By:
Pageof 9
Zhonghua Xue Ye Xue Za Zhi = Zhonghua Xueyexue Zazhi|April 29, 2021
[Hereditary coagulation factor XIII deficiency: three cases report and literaure review]P P Xu, B J Ding, M J Li, et al.
Journal of Synchrotron Radiation|December 20, 2008
Correlation between local vibrations and metal mass in AlB2-type transition-metal diboridesW S Chu, S Zhang, M J Yu, et al.
Zhonghua Xue Ye Xue Za Zhi = Zhonghua Xueyexue Zazhi|January 28, 2023
[Observational study of chronic myeloid leukemia Chinese patients who discontinued tyrosine kinase inhibitors in the real-world]H F Zhao, Y F Yang, B C Liu, et al.
Zhonghua Yi Xue Za Zhi|June 12, 2022
[Analysis the influence factors of treatment free remission outcome with chronic myeloid leukemia patients who discontinued tyrosine kinase inhibitors]H F Zhao, Yanli Zhang, L X Dang, et al.
Zhonghua Xue Ye Xue Za Zhi = Zhonghua Xueyexue Zazhi|November 17, 2021
[CMV-CTL for treatment of refractory CMV infection in 17 patients following alternative donor hematopoietic stem cell transplantation]R R Gui, Z Li, Y L Zu, et al.
Zhonghua Yi Xue Za Zhi|November 5, 2024
[Analysis of treatment-free remission outcomes in patients with chronic myeloid leukemia who received sequential nilotinib therapy after achieving deep molecular response to imatinib]H F Zhao, H B Dang, L X Liang, et al.
Zhonghua Xue Ye Xue Za Zhi = Zhonghua Xueyexue Zazhi|May 21, 2019
[Successful treatment of Epstein-Barr virus associated central nervous system diseases after allogeneic hematopoietic stem cell transplantation with intrathecal donor lymphocytes infusion: three cases report and literatures review]R R Gui, Y L Zu, Yanli Zhang, et al.
Zhonghua Xue Ye Xue Za Zhi = Zhonghua Xueyexue Zazhi|October 30, 2018
[Clinical analysis of six cases with the <i>de novo</i> glomerulitis after allogeneic hematopoietic stem cell transplantation]J Zhou, Y L Zu, R R Gui, et al.
Zhonghua Nei Ke Za Zhi|January 5, 2021
[Risk factors of extramedullary relapse after allogeneic hematopoietic stem cell transplantation in patients with myeloid leukemia]Y L Zu, J Zhou, Yanli Zhang, et al.
Zhonghua Xue Ye Xue Za Zhi = Zhonghua Xueyexue Zazhi|October 27, 2025
[Identify the factors associated with treatment-free remission outcomes after imatinib discontinuation in children and adolescent patients with chronic myeloid leukemia]H F Zhao, Q Jiang, W M Li, et al.
Pageof 9